Yan Zhou1, Taylor Follansbee2, Xuesong Wu3, Dan Han1, Sebastian Yu3, Dan T Domocos2, Zhenrui Shi3, Mirela Carstens2, Earl Carstens2, Samuel T Hwang4. 1. Department of Dermatology, University of California, Davis, CA, USA; Department of Dermatology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi Province, China. 2. Department of Neurobiology, Physiology and Behavior, University of California, Davis, CA, USA. 3. Department of Dermatology, University of California, Davis, CA, USA. 4. Department of Dermatology, University of California, Davis, CA, USA. Electronic address: sthwang@ucdavis.edu.
Abstract
BACKGROUND: Transient Receptor Potential Vanilloid 1 (TRPV1) is known to mediate itch and neurogenic inflammation, but the role of TRPV1 in psoriasiform dermal inflammation is poorly understood. OBJECTIVE: To investigate the function of TRPV1 in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) in mice. METHODS: Following daily treatment of topical IMQ cream for consecutive 5 days in C57BL/6 wide-type (WT) and TRPV1 gene knockout (KO) mice, we assessed the psoriasis severity index (PSI) scores, transepidermal water loss (TEWL), dermal inflammatory infiltrates, as well as gene expression levels for psoriasis related genes in mouse skin lesions. RESULTS: Compared with WT mice, the clinical and TEWL scores, the extent of skin hyperplasia, the area of Munro microabscesses (MM) and angiogenesis of psoriasis were all significantly decreased in TRPV1 KO mice triggered with IMQ, suggesting a reduction in skin inflammation and barrier defects. In addition, the infiltration of CD45+ leukocytes, mast cells as well as CD3+ T cells was all reduced in the IMQ-treated skin of TRPV1 KO mice. Quantitative Real-time PCR (RT-qPCR) revealed that expression levels of IL-1β, IL-6, IL-23, S100A8 were decreased while IL-10 was increased in TRPV1 KO mice. CONCLUSIONS: In summary, key markers of psoriatic inflammation and epidermal hyperplasia are reduced in TRPV1 KO mice, indicating the involvement of TRPV1 in the psoriasiform inflammation and suggesting its potential as a therapeutic target.
BACKGROUND:Transient Receptor Potential Vanilloid 1 (TRPV1) is known to mediate itch and neurogenic inflammation, but the role of TRPV1 in psoriasiform dermal inflammation is poorly understood. OBJECTIVE: To investigate the function of TRPV1 in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) in mice. METHODS: Following daily treatment of topical IMQ cream for consecutive 5 days in C57BL/6 wide-type (WT) and TRPV1 gene knockout (KO) mice, we assessed the psoriasis severity index (PSI) scores, transepidermal water loss (TEWL), dermal inflammatory infiltrates, as well as gene expression levels for psoriasis related genes in mouseskin lesions. RESULTS: Compared with WT mice, the clinical and TEWL scores, the extent of skin hyperplasia, the area of Munro microabscesses (MM) and angiogenesis of psoriasis were all significantly decreased in TRPV1 KO mice triggered with IMQ, suggesting a reduction in skin inflammation and barrier defects. In addition, the infiltration of CD45+ leukocytes, mast cells as well as CD3+ T cells was all reduced in the IMQ-treated skin of TRPV1 KO mice. Quantitative Real-time PCR (RT-qPCR) revealed that expression levels of IL-1β, IL-6, IL-23, S100A8 were decreased while IL-10 was increased in TRPV1 KO mice. CONCLUSIONS: In summary, key markers of psoriatic inflammation and epidermal hyperplasia are reduced in TRPV1 KO mice, indicating the involvement of TRPV1 in the psoriasiform inflammation and suggesting its potential as a therapeutic target.
Authors: Leigh A Nattkemper; Hong Liang Tey; Rodrigo Valdes-Rodriguez; Helen Lee; Nicholas K Mollanazar; Christian Albornoz; Kristen M Sanders; Gil Yosipovitch Journal: J Invest Dermatol Date: 2018-01-06 Impact factor: 8.551
Authors: Petra C Arck; Andrzej Slominski; Theoharis C Theoharides; Eva M J Peters; Ralf Paus Journal: J Invest Dermatol Date: 2006-08 Impact factor: 8.551
Authors: Lorena Riol-Blanco; Jose Ordovas-Montanes; Mario Perro; Elena Naval; Aude Thiriot; David Alvarez; Silke Paust; John N Wood; Ulrich H von Andrian Journal: Nature Date: 2014-04-23 Impact factor: 49.962
Authors: László Pecze; Péter Pelsoczi; Miklós Kecskés; Zoltán Winter; András Papp; Krisztián Kaszás; Tamás Letoha; Csaba Vizler; Zoltán Oláh Journal: Can J Neurol Sci Date: 2009-03 Impact factor: 2.104
Authors: Steven R Feldman; Donald M Bushnell; Paul A Klekotka; Michael Scanlon; Mona L Martin; Sally W Wade; Wenjing Yang; Lionel Pinto; Leon Kircik; Hema N Viswanathan Journal: J Dermatolog Treat Date: 2015-10-07 Impact factor: 3.359
Authors: Jonathan A Cohen; Tara N Edwards; Andrew W Liu; Toshiro Hirai; Marsha Ritter Jones; Jianing Wu; Yao Li; Shiqun Zhang; Jonhan Ho; Brian M Davis; Kathryn M Albers; Daniel H Kaplan Journal: Cell Date: 2019-07-25 Impact factor: 41.582
Authors: Xuan Zhang; Jiali Cao; Siqi Zhao; Xutong Yang; Jie Dong; Yaqi Tan; Teng Yu; Yanling He Journal: Front Immunol Date: 2021-10-22 Impact factor: 7.561